Saint InBio SGB-7342 (INHBE siRNA) completes first subject dosing
36Kr learned that on January 13, Shengyin Biotech announced that its self-developed small interfering RNA (siRNA) candidate drug SGB-7342 completed the first subject dosing in a Phase 1 clinical study for the treatment of obesity at the First Hospital of Jilin University. This randomized, double-blind, placebo-controlled, single-dose escalation Phase 1 clinical study aims to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of SGB-7342 in overweight and obese patients
Source: 36Kr The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments